{"AmendmentNumber":"1693","ParentBillNumber":"H5500","Bill":null,"Sponsor":{"Id":"MCD1","Name":"Marjorie C. Decker","Type":1,"Details":"https://malegislature.gov/api/GeneralCourts/194/LegislativeMembers/MCD1","ResponseDate":"2026-04-17T16:10:47.663"},"Category":"Constitutional Officers and State Administration","Action":"Consolidated","RollCall":[],"Title":"Maintaining Patient Access to Care","Branch":"House","RedraftNumber":null,"IsFurther":false,"GeneralCourtNumber":194,"Text":"Representatives Decker of Cambridge and Consalvo of Boston move to amend the bill in section 2, in item 1108-5200, in line 39, by inserting after “means” the following: “; provided further, that the commission shall maintain coverage for glucagon-like peptide-1 (GLP-1) receptor agonist medications for the treatment of obesity for all members who do not have an FDA-approved comorbidity”; and moves to further amend the bill in item 4000-0300, in line 160, by inserting after “2027” the following: “; provided further, that the department shall maintain coverage for glucagon-like peptide-1 (GLP-1) receptor agonist medications for the treatment of obesity”.\r\n"}